Life Science companies pioneering exciting innovations are meeting prospective funders and peers tonight at an event at Citylabs 1.0.
Organised by the Oxford Bioscience Network, the Early-Stage R&D Company Showcase Evening, includes Blueberry Therapeutics and OncoTherics who are both based at Alderley Park.
OBN is a not-for-profit membership organisation supporting the UK’s innovative life sciences companies, corporate partners and investors. Its 400-plus member companies stretch from the Golden Triangle, through Manchester right up to Scotland.
Dubbed the ‘upstarts and new member showcase’ the event provides a platform for innovative life-science companies to come together in the heart of Corridor Manchester, the city region’s innovation district.
The evening provides the perfect stage for scientists and entrepreneurs at the helm of these companies to raise their profile within in the industry, share best practice and make valuable networking connections with existing OBN members.
Six early-stage companies are scheduled to deliver presentations on the exciting treatments and technologies they are developing, and the evening will also see a keynote address from Peter Dines of Mercia Fund Management.
As the investment director at the head of the company’s life science division, Peter has more than two decades’ of experience of running successful businesses in the healthcare and biotech sectors.
Thomas Renn, Managing Director of Manchester Science Partnerships said: “We are delighted to support OBN at Citylabs 1.0 and we’re sure that that evening will see some interesting science unveiled and important connections made. It’s great too to see two of our customers from Alderley Park taking part.
“As a knowledge broker, Manchester Science Partnerships is committed to events such as this. They provide the ideal environment for scientists focused on research and development to step out of the lab and meet the experienced investors and commercial partners who can help take their ideas to market.”
Blueberry Therapeutics – a modern drug discovery and development company specialising in nanoparticle drug delivery, focusing on inflammation and infection (Alderley Park)
OncoTherics Ltd – focused on the development of novel hypoxia-activated pro-drugs for the treatment of a wide range of cancers (Alderley Park)
StrataStem – pioneering technologies for manufacturing neurons from stem cells (Manchester)
Oxford Endovascular – developing metallic mesh tube devices to treat patients suffering from brain aneurysms (Oxford)
Orbit Discovery – a peptide display company identifying potential peptide drugs for a range of chronic diseases (Oxford)
Cellomatics Biosciences Ltd – specialised Contract Research Organisation (CRO) providing bespoke immunoassays and cell-based assays (Nottingham)